Pancreatic Cancer Precision Medicine Market Report 2026

The pancreatic cancer precision medicine market size has grown rapidly in recent years. It will grow from $0.58 billion in 2025 to $0.67 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to poor survival rates with conventional therapies, advancements in cancer genomics, increased pancreatic cancer incidence, expansion of oncology research funding, early success of targeted therapies.

The pancreatic cancer precision medicine market size is expected to see rapid growth in the next few years. It will grow to $1.24 billion in 2030 at a compound annual growth rate (CAGR) of 16.6%. The growth in the forecast period can be attributed to growth in precision oncology adoption, rising investment in pancreatic cancer research, advancements in diagnostic technologies, expansion of immunotherapy pipelines, increasing use of companion diagnostics. Major trends in the forecast period include increasing use of genomic and molecular profiling, growing adoption of biomarker-based therapies, expansion of targeted and immunotherapy combinations, rising use of liquid biopsy diagnostics, increasing focus on personalized treatment pathways.

The increasing prevalence of pancreatic cancer is expected to drive the growth of the pancreatic cancer precision medicine market in the coming years. Pancreatic cancer is a malignancy that originates in the tissues of the pancreas, an organ essential for digestion and blood sugar regulation. Its incidence is rising due to an aging population and the growing prevalence of risk factors such as obesity, diabetes, and smoking. Pancreatic cancer precision medicine supports cancer management by providing personalized treatment plans based on genetic and molecular information, improving treatment efficacy while reducing side effects. For example, in February 2025, Cancer Australia, an Australian government agency, reported 4,641 new pancreatic cancer cases in 2024 - 2,414 in males and 2,227 in females - up from 3,968 cases in 2023. Consequently, the rising prevalence of pancreatic cancer is fueling growth in the pancreatic cancer precision medicine market.

Leading companies in the pancreatic cancer precision medicine market are focusing on developing advanced technologies, such as precision medical tools, to improve early detection, enable accurate tumor profiling, and optimize personalized treatment strategies for better patient outcomes. A precision medical tool is a specialized device designed to diagnose and treat diseases accurately based on an individual’s unique biology. For example, in January 2024, Cedars-Sinai, a U.S.-based hospital and healthcare organization, launched the Molecular Twin precision oncology platform, a precision medical tool aimed at better predicting pancreatic cancer survival by identifying key biomarkers. The platform demonstrates strong potential in guiding treatment decisions, even in resource-limited settings, by analyzing blood and tissue samples from 74 patients with pancreatic ductal adenocarcinoma to provide a more accurate and accessible approach to precision oncology.

In January 2024, Bristol Myers Squibb, a U.S.-based biopharmaceutical company developing and commercializing innovative medicines across oncology, immunology, cardiovascular, and other therapeutic areas, acquired Mirati Therapeutics for an undisclosed amount. Through this acquisition, Bristol Myers Squibb gained access to Mirati’s targeted oncology assets, including the commercial KRAS G12C inhibitor Krazati (adagrasib) and a complementary pipeline of KRAS- and PRMT5-focused programs, thereby enhancing its precision oncology capabilities and strengthening its global oncology portfolio. Mirati Therapeutics is a U.S.-based commercial-stage biotechnology company specializing in targeted cancer therapeutics and recognized for its expertise in developing precision oncology programs for KRAS-mutant cancers.

Major companies operating in the pancreatic cancer precision medicine market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc, Novartis AG, Amgen Inc., Eli Lilly and Company, Genentech Inc., Ipsen Pharma, Bayer AG, Thermo Fisher Scientific Inc., Illumina Inc., Guardant Health, Foundation Medicine Inc., Oncolytics Biotech Inc., Erytech Pharma, PharmaCyte Biotech Inc., Celgene Corporation, Natera Inc.

North America was the largest region in the pancreatic cancer precision medicine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pancreatic cancer precision medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pancreatic cancer precision medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pancreatic cancer precision medicine market by increasing the cost of imported genomic testing kits, biologic drugs, and specialized diagnostic reagents used in personalized oncology care. These impacts are most evident in advanced oncology centers across North America, Europe, and Asia Pacific, where precision diagnostics and targeted therapies are widely adopted. Rising tariff related expenses have contributed to higher overall treatment costs and budget pressure for cancer care providers. This has influenced procurement decisions and access planning for precision medicine solutions. However, tariffs have encouraged regional diagnostic innovation, expanded local manufacturing of precision oncology tools, and strengthened long term supply resilience.

The pancreatic cancer precision medicine market research report is one of a series of new reports that provides pancreatic cancer precision medicine market statistics, including pancreatic cancer precision medicine industry global market size, regional shares, competitors with a pancreatic cancer precision medicine market share, detailed pancreatic cancer precision medicine market segments, market trends and opportunities, and any further data you may need to thrive in the pancreatic cancer precision medicine industry. This pancreatic cancer precision medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pancreatic cancer precision medicine is a specialized treatment approach that personalizes care for pancreatic cancer patients. It utilizes genetic and molecular information from the patient and their tumor to develop a tailored treatment plan. This strategy aims to improve patient outcomes by optimizing therapy, minimizing unnecessary treatments, and increasing the likelihood of successful interventions.

The main therapeutic approaches in pancreatic cancer precision medicine include targeted therapy, immunotherapy, chemotherapy-precision combinations, and others. Targeted therapy involves drugs designed to specifically act on genetic mutations, proteins, or other molecules that drive cancer growth and spread. These treatments are supported by diagnostic technologies such as genomic testing, molecular diagnostics, liquid biopsies, and biomarker-based companion diagnostics. These therapies and technologies are applied in settings including hospitals, specialty clinics, academic and research institutes, and diagnostic centers.

The pancreatic cancer precision medicine market includes revenues earned by entities by providing services such as personalized treatment planning, tumour molecular profiling, precision imaging and diagnostics, and targeted therapeutics. The market value includes the value of related goods sold by the service provider or included within the service offering. The pancreatic cancer precision medicine market consists of sales of genetic and biomarker testing kits, immunotherapy drugs, and personalized cancer vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.